Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk Ventilation 81% Severe case 33% HCQ for COVID-19  Alzahrani et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 47 patients in Saudi Arabia Lower ventilation with HCQ (not stat. sig., p=0.54) c19hcq.org Alzahrani et al., Rheumatology Int. , Apr 2021 Favors HCQ Favors control

Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases

Alzahrani et al., Rheumatology International , doi:10.1007/s00296-021-04857-9
Apr 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 47 rheumatic disease patients not finding significant differences with HCQ.
risk of death, 58.7% lower, RR 0.41, p = 1.00, treatment 0 of 14 (0.0%), control 1 of 33 (3.0%), NNT 33, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 81.0% lower, RR 0.19, p = 0.54, treatment 0 of 14 (0.0%), control 3 of 33 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of severe case, 32.7% lower, RR 0.67, p = 0.70, treatment 2 of 14 (14.3%), control 7 of 33 (21.2%), NNT 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alzahrani et al., 15 Apr 2021, retrospective, Saudi Arabia, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases
Zeyad A Alzahrani, Khalid Abdullah Alghamdi, Ahmed Saeed Almaqati
Rheumatology International, doi:10.1007/s00296-021-04857-9
This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients' demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.
References
Ahmed, Gasparyan, Zimba, Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic, Rheumatol Int, doi:10.1007/s00296-020-04764-5
Fernandez-Gutierrez, Leon, Madrid, Rodriguez-Rodriguez, Freites et al., Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents, Ther Adv Musculoskelet Dis
Fredi, Cavazzana, Moschetti, Andreoli, Franceschini et al., COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study, Lancet Rheumatol
Gianfrancesco, Hyrich, Al-Adely, Carmona, Danila et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in immune-mediated inflammatory diseasescase series from New York, N Engl J Med
Hasseli, Mueller-Ladner, Schmeiser, Hoyer, Krause et al., National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD, RMD Open, doi:10.1136/rmdopen-2020-001332
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Loarce-Martos, García-Fernández, López-Gutiérrez, García-García, Calvo-Sanz et al., High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study, Rheumatol Int
Malgie, Schoones, Pijls, Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies, Clin Infect Dis Sep, doi:10.1093/cid/ciaa1445
Montero, Martínez-Barrio, Serrano-Benavente, González, Rivera et al., Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes, Rheumatol Int
Nuñez, Leon, Mucientes, Rodriguez-Rodriguez, Urgelles et al., Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis
Pablos, Galindo, Carmona, Lledó, Retuerto et al., Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study, Ann Rheum Dis
Patanavanich, Glantz, Smoking is associated with COVID-19 progression: a meta-analysis, Nicotine Tob Res
Putman, Chock, Tam, Kim, Sattui et al., Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis, Arthritis Rheumatol
Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with Covid-19, doi:10.1056/NEJMoa2021436
Rocha, Atallah, Pinto, Rocha-Filho, Milby et al., COVID-19 and patients with immunemediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review, Sao Paulo Med J
Sanchez-Piedra, Diaz-Torne, Manero, Pego-Reigosa, Rúa-Figueroa et al., Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies, Ann Rheum Dis
Santos, Férnandez, Morales, Álvarez, Castro et al., Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?, RMD Open
Santos, Morales, Álvarez, Castro, Robles et al., Determinants of COVID-19 disease severity in patients with underlying rheumatic disease, Clin Rheumatol
Silva, Boyd, Wallwork, Hsu, Fu et al., Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot, Ann Rheum Dis
Strangfeld, Schäfer, Gianfrancesco, Lawson-Tovey, Liew et al., Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ
Wang, He, Yu, Hu, Bao et al., Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up, J Infect
Zhong, Shen, Yang, Huang, Chen et al., COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study, Lancet Rheumatol
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit